QAAGZX Fees and Costs — T. Rowe Price Health Sciences Portfolio
Data updated: 2026-08-27
The net expense ratio is 0.86%: a 0.65% management fee plus 0.21% other expenses. There are no sales loads or redemption fees. In fiscal 2025 the fund paid $196K in broker commissions, 0.0293% of average net assets, and portfolio turnover was 65%.
QAAGZX Fees and Expenses
Annual operating expenses and sales charges of QAAGZX. Prospectus, as of April 24, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.65% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.21% |
| Gross expense ratio | 0.86% |
| Fee waiver | — |
| Net expense ratio | 0.86% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
QAAGZX Costs Over Time
On $10,000 invested in QAAGZX, assuming 5% a year before costs, total costs come to $557 over 5 years, cutting the return by 0.93% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.86%) | $90 | $282 | $490 |
| Trading costs (broker commissions) | $3 | $10 | $17 |
| Lost growth on money paid in costs | $0 | $14 | $51 |
| Total costs | $93 | $306 | $557 |
| Value after costs | $10,407 | $11,270 | $12,205 |
| Impact on return, per year | 0.93% | 0.93% | 0.93% |
QAAGZX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending December 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.0293%
- Total broker commissions: $196K
- Bought from dealers (principal trades, not a cost): $16.4M
- Portfolio turnover (prospectus): 65%
- Securities lending: none during the year
QAAGZX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| JEFFERIES LLC | $22K | 17.91% |
| RBC Capital Markets, LLC | $15K | 11.86% |
| UBS AG | $13K | 10.68% |
| BOFA SECURITIES, INC. | $13K | 10.67% |
| MORGAN STANLEY & CO. LLC | $12K | 9.91% |
| GOLDMAN SACHS & CO. LLC | $11K | 9.05% |
| TD Securities Ltd. | $11K | 8.80% |
| Citigroup Inc. | $9K | 7.45% |
| J.P. MORGAN SECURITIES LLC | $9K | 7.35% |
| Virtu ITG Hong Kong Limited | $8K | 6.32% |
QAAGZX Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| LEERINK PARTNERS LLC | $3.0M | 22.00% |
| JEFFERIES LLC | $2.2M | 16.73% |
| J.P. MORGAN SECURITIES LLC | $1.6M | 12.12% |
| GOLDMAN SACHS & CO. LLC | $1.4M | 10.35% |
| TD Securities Ltd. | $1.2M | 9.17% |
| MORGAN STANLEY & CO. LLC | $1.2M | 8.61% |
| Guggenheim Securities, LLC | $928K | 6.90% |
| BOFA SECURITIES, INC. | $852K | 6.34% |
| STIFEL NICOLAUS EUROPE LIMITED | $560K | 4.16% |
| PIPER SANDLER & CO. | $486K | 3.62% |
T. Rowe Price Health Sciences Portfolio Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| QAAGZX | T. Rowe Price Health Sciences Portfolio | 0.86% | — |
| QAAHBX | Class II | 1.11% | — |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.